|Bid||85.00 x 0|
|Ask||87.00 x 0|
|Day's range||85.00 - 89.70|
|52-week range||39.10 - 202.00|
|Beta (5Y monthly)||1.37|
|PE ratio (TTM)||23.64|
|Earnings date||07 Aug 2019|
|Forward dividend & yield||N/A (N/A)|
|1y target est||70.00|
Finding stocks that have both positive share price momentum and improving financial health trends is a great way of finding pockets of quality and momentum in8230;
Carl Sterritt became the CEO of Shield Therapeutics plc (LON:STX) in 2008. This analysis aims first to contrast CEO...
Anyone researching Shield Therapeutics plc (LON:STX) might want to consider the historical volatility of the share...
In 2008 Carl Sterritt was appointed CEO of Shield Therapeutics plc (LON:STX). This analysis aims first to contrast CEO...
Hardman & Co Research 05-Aug-2019 / 11:22 GMT/BST * * *Hardman & Co: FDA approval opens door to major US opportunityShield Therapeutics (STX) is a commercial-stage pharmaceutical company delivering specialty products that address patients' unmet medical needs, with an initial focus on treating iron deficiency (ID) with Feraccru(R)/Accufer(R). News that the FDA has approved this drug for a broad indication opens it up to a commercial market worth over $1bn. STX has been in discussions with a number of potential partners, but its hand has been strengthened by the regulatory de-risking of Accufer. Its USP will be that oral Accufer is as effective as intravenous iron. The market capitalisation equates to only 4.4x in-market sales.Please click here for the full report:https://www.hardmanandco.com/research/corporate-research/fda-approval-opens-door-to-major-us-opportunity/To contact us:Hardman & Co 35 New Broad Street London EC2M 1NHwww.hardmanandco.comFollow us on Twitter @HardmanandCoContacts:Dr Martin HallDr Dorothea HillDr Gregoire Pave +44 20 7194 7622 email@example.com firstname.lastname@example.org email@example.com Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the world with high-quality research, investor engagement programmes and advisory services. Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer. * * *Dissemination of a CORPORATE NEWS, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. * * * End of Announcement - EQS News Service
If you want to know who really controls Shield Therapeutics plc (LON:STX), then you'll have to look at the makeup of...
Anyone researching Shield Therapeutics plc (LON:STX) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. Investors may think of volatility...